arrow
B

Byung Ha Chung

Yonsei University
H指数:42
被引数:8,661

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

联合使用度他雄胺和他达拉非治疗良性前列腺增生:一项随机III期临床试验,与度他雄胺或他达拉非单药治疗相比

2026-02-100
OAAI
Skin rash in metastatic hormone sensitive prostate cancer patients treated with apalutamide: a retrospective multicenter study in Korea

阿帕卢他胺治疗激素敏感性转移性前列腺癌患者的皮肤 rash:一项韩国多中心回顾性研究

2024-11-010
OAAI
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer

SPARTAN和TITAN晚期前列腺癌患者快速和深度前列腺特异性抗原下降和患者报告的健康相关生活质量的事后分析

2024-08-015
PRE
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry

主动监测前列腺癌是否已变得更安全?全球临床登记研究的经验教训

2024-07-010
OAAI
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

阿帕鲁胺治疗的前列腺特异性抗原 (PSA) 下降与转移性前列腺癌患者的生存期延长和预后改善有关: TITAN研究的简明语言总结

2023-12-210
OA
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial

阿帕鲁胺治疗转移性去势敏感性前列腺癌: TITAN试验中亚洲亚群的最终分析

2023-06-063
OAAI
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
2023-05-0134
OA